| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 63,734 | 52,698 | 52,783 | 108,845 |
| Depreciation | 70 | 72 | 72 | 231 |
| Stock-based compensation | 6,260 | 5,661 | 5,670 | 13,447 |
| Amortization of intangible assets | 9,703 | 9,465 | 9,344 | 18,689 |
| Inventory reserve and write-offs | NaN | 83 | -292 | 673 |
| Deferred taxes | 2,336 | 4,511 | -2,417 | 4,755 |
| Accretion of discount | 135 | 116 | 96 | 138 |
| Reduction in the carrying amount of right-of-use asset | 77 | 75 | 74 | 146 |
| Acquired inventory samples expensed from asset acquisition | NaN | 0 | NaN | NaN |
| Acquired in-process research and development | NaN | 0 | NaN | NaN |
| Change in fair value of equity securities | 4,750 | 3,369 | -2,089 | -308 |
| Accounts receivable, net | 4,357 | 20,068 | 40,546 | 387 |
| Inventory | -2,236 | 9,220 | 9,087 | -218 |
| Prepaid expenses and other current assets | -2,449 | -6,907 | 6,697 | 387 |
| Accounts payable | -4,051 | 2,106 | 3,568 | -11,065 |
| Accrued expenses and other liabilities | -9,207 | 5,210 | 13,241 | 5,713 |
| Operating lease liability | -106 | -102 | -102 | -197 |
| Net cash provided by (used in) operating activities | 59,587 | 44,891 | 32,438 | 131,341 |
| Purchases of property and equipment | 27 | 32 | 0 | 26 |
| Payments in connection with asset acquisitions | NaN | 0 | NaN | NaN |
| Acquisition of in-process research and development | NaN | 0 | NaN | NaN |
| Purchase of equity securities | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock | NaN | 0 | 0 | 0 |
| Net cash provided by (used in) investing activities | -27 | -32 | 0 | -26 |
| Payment of employee withholding tax related to stock-based compensation | 301 | 912 | 0 | 861 |
| Proceeds from exercise of stock options | 3,302 | 1,876 | 5,796 | 6,997 |
| Payment of fees in connection with issuance of common stock | NaN | 0 | 0 | 0 |
| Repurchase of common stock | 14,574 | 25,300 | NaN | NaN |
| Payment of liabilities arising from asset acquisition | 1,299 | 1,244 | 1,142 | 2,204 |
| Net cash provided by (used in) financing activities | -12,872 | -25,580 | 4,654 | 3,932 |
| Net increase (decrease) in cash and cash equivalents | 46,688 | 19,279 | 37,092 | 135,247 |
| Cash and cash equivalents beginning of period | 709,171 | 689,892 | 517,553 | NaN |
| Cash and cash equivalents end of period | 755,859 | 709,171 | 689,892 | NaN |
CATALYST PHARMACEUTICALS, INC. (CPRX)
CATALYST PHARMACEUTICALS, INC. (CPRX)